Repligen (FRA:RGN) Cyclically Adjusted FCF per Share: €0.93 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RGN Repligen Corp FRA:RGN
87 GF Score
Price €126.20
GF Value €139.01
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Repligen Cyclically Adjusted FCF per Share?

Repligen FRA:RGN +10.95% 87 Cyclically Adjusted FCF per Share is €0.93 as of Mar. 2026. GuruFocus rates FRA:RGN with a GF Score™ of 87/100 and a GF Value™ of €139.01 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Repligen's adjusted free cash flow per share for the three months ended in Mar. 2026 was €0.356. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.93 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Repligen's average Cyclically Adjusted FCF Growth Rate was 17.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 19.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 17.70% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 14.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Repligen was 146.60% per year. The lowest was -6.30% per year. And the median was 18.45% per year.

As of today (2026-07-30), Repligen's current stock price is €126.20. Repligen's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €0.93. Repligen's Cyclically Adjusted Price-to-FCF of today is 135.70.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 77.34. And the median was 225.33.


Repligen  (FRA:RGN) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Repligen's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=126.20/0.93
=135.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Repligen was 621.65. The lowest was 77.34. And the median was 225.33.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Repligen Cyclically Adjusted FCF per Share Related Terms


Repligen Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Repligen's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Repligen Cyclically Adjusted FCF per Share Chart

Repligen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.49 0.58 0.64 0.88 0.90

Repligen Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.93 0.82 0.81 0.90 0.93

FRA:RGN vs AVTR, ATR, TFX: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, Repligen's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Repligen Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Repligen's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Repligen's Cyclically Adjusted Price-to-FCF falls into.


FRA:RGN
87GF Score
Repligen Corp FRA:RGN
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Repligen Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Repligen's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.356/330.2130*330.2130
=0.356

Current CPI (Mar. 2026) = 330.2130.

Repligen Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.250 241.018 0.343
201609 -0.084 241.428 -0.115
201612 0.030 241.432 0.041
201703 -0.004 243.801 -0.005
201706 0.036 244.955 0.049
201709 -0.054 246.819 -0.072
201712 0.256 246.524 0.343
201803 0.000 249.554 0.000
201806 0.059 251.989 0.077
201809 0.290 252.439 0.379
201812 0.002 251.233 0.003
201903 0.114 254.202 0.148
201906 0.225 256.143 0.290
201909 0.264 256.759 0.340
201912 0.179 256.974 0.230
202003 0.077 258.115 0.099
202006 0.204 257.797 0.261
202009 0.260 260.280 0.330
202012 0.047 260.474 0.060
202103 0.003 264.877 0.004
202106 0.299 271.696 0.363
202109 0.161 274.310 0.194
202112 0.249 278.802 0.295
202203 -0.079 287.504 -0.091
202206 0.325 296.311 0.362
202209 -0.284 296.808 -0.316
202212 0.670 296.797 0.745
202303 0.028 301.836 0.031
202306 0.407 305.109 0.440
202309 0.497 307.789 0.533
202312 0.295 306.746 0.318
202403 0.591 312.332 0.625
202406 0.573 314.175 0.602
202409 0.679 315.301 0.711
202412 0.497 315.605 0.520
202503 0.173 319.799 0.179
202506 0.322 322.561 0.330
202509 0.644 324.800 0.655
202512 0.262 324.054 0.267
202603 0.356 330.213 0.356

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €0.93 mean?
Repligen (FRA:RGN) has a Cyclically Adjusted FCF per Share of €0.93 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Repligen and its competitors.
Is Repligen's Cyclically Adjusted FCF per Share too high?
Repligen's current Cyclically Adjusted FCF per Share is €0.93. Overall, Repligen has a GF Score™ of 87/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Repligen's Cyclically Adjusted FCF per Share compare to AVTR and ATR?
Repligen's Cyclically Adjusted FCF per Share of €0.93 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Repligen and its competitors. Repligen's current Cyclically Adjusted FCF per Share is €0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Repligen stock overvalued right now?
Based on GuruFocus' analysis, Repligen (FRA:RGN) is currently considered Fairly Valued. The stock's GF Value™ is €139.01, compared to a current price of €126.20 — trading 9.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €0.93. Repligen's overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Repligen (FRA:RGN), the current Cyclically Adjusted FCF per Share is €0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Repligen (FRA:RGN) Overvalued in 2026?

Based on GuruFocus' analysis, Repligen stock appears to be undervalued. The current stock price of €126.20 is trading 9.2% below its estimated GF Value™ of €139.01. GuruFocus considers Repligen to be Fairly Valued.

Key valuation signals for FRA:RGN:

  • Cyclically Adjusted FCF per Share: €0.93
  • GF Value™: €139.01 vs. price of €126.20 (9.2% below fair value)
  • GF Score™: 87/100 with 5 warning signs

No single metric tells the full story. See the FRA:RGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Repligen Business Description

Other Exchanges RGEN:USA
Address 41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
87GF Score

Get the complete analysis for FRA:RGN

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€126.20
Price
€139.01
GF Value